精彩内容7月17日,华东医药旗下博华制药和中美华东联合提交了阿帕他胺片的4类仿制上市申请。阿帕他胺是强生的重磅内分泌治疗用药,2024年在全球的销售额接近30亿美元、在中国三大终端六大市场的销售额已达到了7亿元。图1:华东医药最新申报的产品来源:CDE官网图2:阿帕他胺的全球销售情况来源:米内网跨国上市公司数据库阿帕他胺作为新一代口服雄激素受体(AR)抑制剂,在治疗非转移性去势抵抗性前列腺癌方面...
Source Link精彩内容7月17日,华东医药旗下博华制药和中美华东联合提交了阿帕他胺片的4类仿制上市申请。阿帕他胺是强生的重磅内分泌治疗用药,2024年在全球的销售额接近30亿美元、在中国三大终端六大市场的销售额已达到了7亿元。图1:华东医药最新申报的产品来源:CDE官网图2:阿帕他胺的全球销售情况来源:米内网跨国上市公司数据库阿帕他胺作为新一代口服雄激素受体(AR)抑制剂,在治疗非转移性去势抵抗性前列腺癌方面...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.